TITLE

WOW SALE BOOSTS KNOLOGY SHARES

PUB. DATE
April 2006
SOURCE
Multichannel News;4/10/2006, Vol. 27 Issue 15, p119
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the impact of the sale of overbuilder WideOpenWest on the shares of Knology Inc. in April 2006. Threat faced by the company's operations from hurricanes; Percentage increase of the value of Knology stocks between December 30, 2005 and April 6, 2006; Value of the sale of WideOpenWest to Avista Capital Partners.
ACCESSION #
20448825

 

Related Articles

  • WideOpenWest Fetches $800M. Farrell, Mike // Multichannel News;12/19/2005, Vol. 26 Issue 53, p10 

    The article reports on the agreement of WideOpenWest to sell its cable television subscribers to Avista Capital Partners, a private equity firm. It is estimated that the agreement would increase the cash flow of WideOpenWest. The deal, according to analyst Aryeh Bourkoff, represents a resurgence...

  • Sold!  // CableFAX Daily;12/15/2005, Vol. 16 Issue 242, p2 

    The article reports on the acquisition of over builder WideOpenWest (WOW) by Avista Capital Partners in 2005. WOW was purchased from Oak Hill Capital Partners and ABRY Partners. According to the previous owners, the change in ownership will be transparent to employees and customers, which means...

  • Bristol-Myers to sell its ConvaTec unit.  // Medical Technology & Devices Week;5/12/2008, Vol. 6 Issue 19, p3 

    This article reports on the move of Bristol-Myers Squibb to sign a definitive agreement to sell its ConvaTec business unit to private equity firms Nordic Capital Fund VII and Avista Capital Partners. Accordingly, the deal is worth $4 billion. The reason of Bristol-Myers Squibb for selling...

  • Boston Scientific closes sale of 2 units to Avista for $425 million.  // Medical Device Daily;2/15/2008, Vol. 12 Issue 32, p1 

    The article reports on the completion of the sale of Boston Scientific's Fluid Management and Venous Access businesses to Avista Capital Partners. Boston claims that the sale has divested all five nonstrategic units it had previously planned to divest and it expects to record an after-tax gain...

  • Boston Sci divests 2 businesses to Avista for $425 million in cash. Johnson, Holland // Medical Device Daily;12/17/2007, Vol. 11 Issue 228, p1 

    The article reports that Boston Scientific has signed a deal to sell its fluid management and venous access businesses for $425 million in cash to private equity company Avista Capital Partners. The deal is expected to be finalized in the first quarter of 2008. Boston Scientific's intent to sell...

  • Boston Scientific closes sale of 2 units for $425M.  // Medical Technology & Devices Week;2/19/2008, Vol. 6 Issue 7, p5 

    This article reports on the sale of the Fluid Management and Venous Access businesses of Boston Scientific to Avista Capital Partners. The business units were sold for $425 million. Boston Scientific sold the business units a part of its plan to divest non-strategic assets. According to Jim...

  • Subsidiary For Sale: Invitrogen Corp. Graves, Brad // San Diego Business Journal;2/19/2007, Vol. 28 Issue 8, p46 

    The article announces the plan of Invitrogen Corp. to sell its business unit, BioReliance Corp. to Avista Capital Partners company in Carlsbad, California. Invitrogen is selling the business for $210 million. The seller also disclosed that it had posted a net loss of $191 million and revenue of...

  • Avista nets 2 Boston Sci businesses for $425M.  // Medical Technology & Devices Week;12/26/2007, Vol. 5 Issue 50, p2 

    The article reports on the agreement signed by Boston Scientific to sell its fluid management and venous access businesses for $425 million in cash to Avista Capital Partners, a private equity firm in the U.S. According to reports, the transaction is expected to close in the first quarter of...

  • Boston Sci sells two units, completing plan of divestitures.  // Cardiovascular Devices & Drugs;Feb2008, Vol. 14 Issue 2, p22 

    The article reports that medical device maker Boston Scientific has completed the sale of its Fluid Management and Venous Access businesses to Avista Capital Partners for $425 million in cash. The move was part of the company's plan to divest non-strategic assets. According to Jim Tobin,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics